Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study

OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated...
May 31, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical

$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first...
May 30, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones

CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
May 15, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Reports First Quarter 2023 Results and Provides Business Update

OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million...
May 09, 2023 07:00 ET | Source: Trevena, Inc.

Trevena to Release First Quarter 2023 Financial Results on May 15, 2023

CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
May 08, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Announces Approval of OLINVYK in China

Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15...
May 03, 2023 07:00 ET | Source: Trevena, Inc.

Trevena to Participate in Three Upcoming Conferences

CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
March 30, 2023 07:02 ET | Source: Trevena, Inc.

Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study

OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on...
March 30, 2023 07:00 ET | Source: Trevena, Inc.

Trevena Reports Fourth Quarter 2022 Results and Provides Business Update

Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor...
March 27, 2023 07:00 ET | Source: Trevena, Inc.

Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

CHESTERBROOK, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...